Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis
CK0804 is an allogeneic, off‑the‑shelf Treg cell therapy.
Drug Development
Zai Lab’s Augtyro receives NMPA approval for solid tumours in China
Takeda and Protagonist seek FDA approval for rusfertide to treat PV
Arrowhead receives Health Canada authorisation for Redemplo to treat FCS
Insilico and Servier announce $888m oncology research agreement
Samsung Bioepis initiates Byooviz commercialisation in Europe
Outlook Therapeutics receives FDA response on ONS-5010 for wet AMD
Emmaus, NIT sign Endari distribution agreement
